San Carlos, United States
CuraSen Therapeutics, Inc. is a privately funded biopharmaceutical company founded in 2017 and headquartered in the United States.
The company's mission is encapsulated in its slogan: "Targeting neurodegeneration with novel science and treatments so patients can THINK, AGAIN." CuraSen focuses on developing innovative treatments for neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, and several rare conditions.
Recognizing the increasing burden of these diseases, CuraSen is pioneering a therapeutic approach involving the restoration of a critical brain pathway associated with the locus coeruleus (LC). Clinical testing began in 2019, leveraging existing drugs from other areas, and led to the advancement of their first new chemical entity, CST-2032, into clinical trials by September 2020.
The company benefits from a seasoned team experienced in neuroscience, pharmacology, and clinical development, with investment support from prominent backers, namely New Leaf Venture Partners, Longitude Capital, and others. CuraSen's recent venture includes a $5.80M grant investment from the Alzheimer's Drug Discovery Foundation as of October 2023.
Neumora
